IP Library Granted Patent US 7,435,425
Granted Patent B2
US 7,435,425 · App. 09/908,464 · Granted Oct 14, 2008

Dry hemostatic compositions and methods for their preparation

Assignees: Baxter International, Inc.; Baxter Healthcare S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,435,425
App. No.
09/908,464
Granted
Oct 14, 2008
Kind
B2
Abstract

Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.

Claims (31)

1. A composition comprising an aqueous solution of non-cross-linked gelatin and a re-hydration aid, wherein the non-cross-linked gelatin is present in the aqueous solution in the range from 5% (w/w) to 15% (w/w), and the rehydration aid comprises PEG in the range from 2.5% (w/w) to 20% (w/w) based on the weight of the gelatin, PVP in the range from 1.25% (w/w) to 20% (w/w) based on the weight of the gelatin, and dextran in the range from 1.25% (w/w) to 20% (w/w) based on the weight of the gelatin.

2. The composition as in claim 1 , wherein the rehydration aid is present in the aqueous solution in the range from 5% to 30% (w/w) based on the weight of gelatin.

3. The composition as in claim 1 , wherein the PEG has an average molecular weight of about 1000.

4. The composition as in claim 1 , wherein the PVP has an average molecular weight of about 50,000.

5. The composition as in claim 1 , wherein the dextran has an average molecular weight of about 40,000.

6. The composition as in claim 1 , further comprising a cross-linking agent.

7. The composition as in claim 1 , further comprising a bifunctional cross-linking agent.

8. The composition as in claim 7 , wherein the bifunctional cross-linking agent comprises a member selected from the group consisting of an aldehyde, an epoxy, a succinimide, a carbodiimide, a maleimide, an azide, a carbonate, an isocyanate, a divinyl sulfone, an alcohol, an amine, an imidate, an anhydride, a halide, a silane, a diazoacetate, and an aziridine.

9. The composition as in claim 1 , further comprising a cross-linking agent, selected from the group consisting of an oxidizer and a periodate.

10. The composition as in claim 1 , wherein the composition comprises a solids content in the range from 1% to 70% by weight.

11. The composition as in claim 1 , wherein the composition comprises a solids content in the range from 3% to 10% by weight.

12. The composition as in claim 1 , further comprising glutaraldehyde.

13. The composition as in claim 12 , wherein the glutaraldehyde is present in the range from 0.01% to 0.05% w/w.

14. The composition as in claim 1 , further comprising a sodium periodate.

15. The composition as in claim 14 , wherein the sodium periodate is present at a concentration of 0.05 M.

16. The composition as in claim 1 , further comprising a 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide.

17. The composition as in claim 16 , wherein the 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide is present in the range from 0.5% to 1.5% w/w.

18. The composition as in claim 1 , wherein the composition comprises an alcohol.

19. The composition as in claim 18 , wherein the alcohol comprises a member selected from the group consisting of a methyl alcohol or an ethyl alcohol.

20. The composition as in claim 18 , wherein the alcohol is present at a solids content in the range from 1% to 70% by weight.

21. The composition as in claim 18 , wherein the alcohol is present at a solids content in the range from 3% to 10% by weight.

22. The composition as in claim 1 , further comprising a glutaraldehyde in the range from 0.01% to 0.1% w/w.

23. The composition as in claim 1 , wherein the composition comprises an aldehyde and has a pH in the range from about 6 to 11.

24. The composition as in claim 1 , wherein the composition comprises an aldehyde and has a pH in the range from 7 to 10.

25. The composition as in claim 1 , further comprising a sodium borohydride.

26. The composition as in claim 1 , wherein the gelatin comprises a bovine gelatin.

27. The composition as in claim 1 , wherein the gelatin is derived from a bovine corium.

28. The composition as in claim 1 , wherein the gelatin is present in the solution in a concentration of approximately 8% w/w.

29. The composition as in claim 1 , wherein the solution comprises a solids content in a range from approximately 3% to 10% w/w.

30. The composition as in claim 1 , wherein the solution comprises a solids content in a range from approximately 7% to 10% w/w.

31. The composition as in claim 1 , wherein the PEG has an average molecular weight of about 400.

Assignments (5)
MERGER Recorded Jan 21, 2010
From: BAXTER HEALTHCARE CORPORATION; FUSION MEDICAL TECHNOLOGIES, INC.
To: BAXTER HEALTHCARE CORPORATION
Reel/Frame 023821/0928 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2010
From: BAXTER HEALTHCARE CORPORATION
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 023828/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2010
From: BAXTER HEALTHCARE CORPORATION
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 023828/0417 →
MERGER Recorded Jan 21, 2010
From: BAXTER HEALTHCARE CORPORATION; FUSION MEDICAL TECHNOLOGIES, INC.
To: BAXTER HEALTHCARE CORPORATION
Reel/Frame 023828/0435 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2001
From: QIAN, ZHEN; OSAWA, A. EDWARD; REICH, CARY J.
To: FUSION MEDICAL TECHNOLOGIES, INC.
Reel/Frame 012285/0754 →
Continuity (1)
Related Publication 20030064109A1 · Apr 3, 2003